The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).
 
Ana Aparicio
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb Pharmaceuticals; Daiichi Sankyo; Genzyme; GlaxoSmithKline; Janssen; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; American Cancer Society; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Daiichi Sankyo Inc.; Genzyme; GlaxoSmithKline; Janssen Research & Development; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Polaris (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; GlaxoSmithKline
 
Rebecca Tidwell
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Zhong He
No Relationships to Disclose
 
Amado Zurita
Honoraria - Amedco; CancerNet; Janssen; McKesson
Consulting or Advisory Role - Bayer; Exelixis; Foundation Medicine; Hikma Pharmaceuticals; Pfizer
Research Funding - Advanced Biochemical Compounds; Astellas Pharma; Clarity Pharmaceuticals; Curium Pharma; Merck; Pfizer
Travel, Accommodations, Expenses - Hikma Pharmaceuticals; Janssen Oncology
 
Bilal Siddiqui
No Relationships to Disclose
 
Sumit Subudhi
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Amgen; Apricity Health; Arcus Biosciences,; AstraZeneca; Baird; Bayer; Boxer Capital; Breaking Data; Bristol-Myers Squibb; Cancer Expert Now; ChemoCentryx; Clinical Comms Group; Dava Oncology; Dendreon; Hervolution Therapeutics; InProTher Janssen; Kahr Medical Ltd; Kiniksa; MacroGenics; MacroGenics; MD Education; Merck; Novartis; OncLive (owned by Intellisphere, LLC); Pfizer; Polaris; Portage Biotech; Regeneron; Rondo
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen; Regeneron
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Regeneron
 
Paul Corn
Research Funding - Janssen Oncology (Inst)
 
Craig Kovitz
Honoraria - Dendreon
Consulting or Advisory Role - Dendreon
 
Bagi Jana
No Relationships to Disclose
 
Andrew Hahn
Honoraria - Binacea; Kaplan Partners in Knowledge; Medscape
Consulting or Advisory Role - AVEO; Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer
Research Funding - Bayer; Eisai (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)
 
Rahul Sheth
Consulting or Advisory Role - Johnson & Johnson/Janssen; Medtronic; TriSalus Life Sciences
Speakers' Bureau - Boston Scientific
Research Funding - Boston Scientific
 
Jessica Deinert
Consulting or Advisory Role - Pfizer
 
Christopher Logothetis
Honoraria - AADi; Amgen; Boehringer Pharma GmbH; GlaxoSmithKline; Janssen Scientific Affairs
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis (Inst); ORIC Pharmaceuticals (Inst)
 
Rama Soundararajan
No Relationships to Disclose
 
Timothy Thompson
Research Funding - Bayer
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Akoya Biosciences; Akoya Biosciences (I); Apricity Health; Apricity Health (I); Bectas (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Matrisome; Oncolytics; Osteologic; Osteologic Therpeutics (I); PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Patrick Pilié
Consulting or Advisory Role - Novartis; Pfizer
Patents, Royalties, Other Intellectual Property - Patent Pending- biomarker